Does the media favor ARVN or CRDL?

In the previous week, Arvinas had 4 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 5 mentions for Arvinas and 1 mentions for Cardiol Therapeutics. Arvinas' average media sentiment score of 0.94 beat Cardiol Therapeutics' score of 0.93 indicating that Arvinas is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arvinas 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cardiol Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, CRDL or CADL?

Candel Therapeutics is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardiol Therapeutics N/A N/A -$24.20M -$0.28 N/A Candel Therapeutics N/A N/A -$38.18M -$0.98 N/A

Is CRDL or CADL more profitable?

Candel Therapeutics' return on equity of -60.42% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cardiol Therapeutics N/A -229.43% -165.60% Candel Therapeutics N/A -60.42% -41.33%

Does the media refer more to CRDL or CADL?

In the previous week, Candel Therapeutics had 5 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 6 mentions for Candel Therapeutics and 1 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.93 beat Candel Therapeutics' score of 0.61 indicating that Cardiol Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiol Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Candel Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ALT or CRDL?

In the previous week, Altimmune had 1 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 2 mentions for Altimmune and 1 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.93 beat Altimmune's score of 0.83 indicating that Cardiol Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Altimmune 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cardiol Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CRDL or VALN?

In the previous week, Valneva had 5 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 6 mentions for Valneva and 1 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.93 beat Valneva's score of 0.38 indicating that Cardiol Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiol Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Valneva 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Cardiol Therapeutics (CRDL) Competitors

$1.16 +0.05 (+4.02%)

As of 11:08 AM Eastern

Compare

CRDL vs. GYRE, ARVN, CADL, ALT, and VALN

Should you buy Cardiol Therapeutics stock or one of its competitors? MarketBeat compares Cardiol Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cardiol Therapeutics include Gyre Therapeutics (GYRE), Arvinas (ARVN), Candel Therapeutics (CADL), Altimmune (ALT), and Valneva (VALN). These companies are all part of the "pharmaceutical products" industry.

How does Cardiol Therapeutics compare to Gyre Therapeutics?

Gyre Therapeutics (NASDAQ:GYRE) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are held by institutional investors. 9.5% of Gyre Therapeutics shares are held by company insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Gyre Therapeutics has a beta of 1.9, meaning that its stock price is 90% more volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market.

Gyre Therapeutics presently has a consensus target price of $17.00, indicating a potential upside of 175.93%. Cardiol Therapeutics has a consensus target price of $8.50, indicating a potential upside of 642.36%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cardiol Therapeutics is more favorable than Gyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Cardiol Therapeutics had 1 more articles in the media than Gyre Therapeutics. MarketBeat recorded 1 mentions for Cardiol Therapeutics and 0 mentions for Gyre Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.93 beat Gyre Therapeutics' score of 0.29 indicating that Cardiol Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Gyre Therapeutics	Neutral
Cardiol Therapeutics	Positive

Cardiol Therapeutics has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -5.44%. Gyre Therapeutics' return on equity of 3.13% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-5.44%	3.13%	2.67%
Cardiol Therapeutics	N/A	-229.43%	-165.60%

Gyre Therapeutics has higher revenue and earnings than Cardiol Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$116.59M	5.13	$5.03M	-$0.09	N/A
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A

Summary

Gyre Therapeutics beats Cardiol Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Arvinas?

Arvinas (NASDAQ:ARVN) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

Arvinas has a beta of 1.74, indicating that its stock price is 74% more volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market.

95.2% of Arvinas shares are owned by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are owned by institutional investors. 7.3% of Arvinas shares are owned by insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Arvinas had 4 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 5 mentions for Arvinas and 1 mentions for Cardiol Therapeutics. Arvinas' average media sentiment score of 0.94 beat Cardiol Therapeutics' score of 0.93 indicating that Arvinas is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arvinas	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cardiol Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arvinas currently has a consensus price target of $15.42, indicating a potential upside of 96.14%. Cardiol Therapeutics has a consensus price target of $8.50, indicating a potential upside of 642.36%. Given Cardiol Therapeutics' higher probable upside, analysts clearly believe Cardiol Therapeutics is more favorable than Arvinas.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arvinas	2 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.46
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Cardiol Therapeutics has a net margin of 0.00% compared to Arvinas' net margin of -247.54%. Arvinas' return on equity of -44.38% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arvinas	-247.54%	-44.38%	-28.38%
Cardiol Therapeutics	N/A	-229.43%	-165.60%

Cardiol Therapeutics has lower revenue, but higher earnings than Arvinas. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arvinas	$262.60M	1.93	-$80.80M	-$3.32	N/A
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A

Summary

Arvinas beats Cardiol Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Candel Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

In the previous week, Candel Therapeutics had 5 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 6 mentions for Candel Therapeutics and 1 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.93 beat Candel Therapeutics' score of 0.61 indicating that Cardiol Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiol Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Candel Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cardiol Therapeutics presently has a consensus price target of $8.50, suggesting a potential upside of 642.36%. Candel Therapeutics has a consensus price target of $18.00, suggesting a potential upside of 97.04%. Given Cardiol Therapeutics' higher possible upside, equities research analysts plainly believe Cardiol Therapeutics is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Candel Therapeutics' return on equity of -60.42% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-229.43%	-165.60%
Candel Therapeutics	N/A	-60.42%	-41.33%

12.5% of Cardiol Therapeutics shares are held by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are held by institutional investors. 5.3% of Cardiol Therapeutics shares are held by company insiders. Comparatively, 14.3% of Candel Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cardiol Therapeutics has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.49, indicating that its stock price is 149% less volatile than the broader market.

Candel Therapeutics is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A

Summary

Candel Therapeutics beats Cardiol Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Altimmune?

Altimmune (NASDAQ:ALT) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

In the previous week, Altimmune had 1 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 2 mentions for Altimmune and 1 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.93 beat Altimmune's score of 0.83 indicating that Cardiol Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Altimmune	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cardiol Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cardiol Therapeutics has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Altimmune	-214,860.98%	-42.57%	-35.57%
Cardiol Therapeutics	N/A	-229.43%	-165.60%

Altimmune has a beta of 0.21, meaning that its stock price is 79% less volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market.

Cardiol Therapeutics has lower revenue, but higher earnings than Altimmune. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altimmune	$40K	14,463.71	-$88.09M	-$0.93	N/A
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A

78.1% of Altimmune shares are owned by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are owned by institutional investors. 1.6% of Altimmune shares are owned by insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Altimmune presently has a consensus target price of $16.67, suggesting a potential upside of 460.22%. Cardiol Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 642.36%. Given Cardiol Therapeutics' higher probable upside, analysts clearly believe Cardiol Therapeutics is more favorable than Altimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Altimmune	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Altimmune beats Cardiol Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Valneva?

Cardiol Therapeutics (NASDAQ:CRDL) and Valneva (NASDAQ:VALN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings.

12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 11.4% of Valneva shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by insiders. Comparatively, 14.9% of Valneva shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Cardiol Therapeutics has a net margin of 0.00% compared to Valneva's net margin of -88.87%. Valneva's return on equity of -107.63% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-229.43%	-165.60%
Valneva	-88.87%	-107.63%	-33.02%

Cardiol Therapeutics currently has a consensus target price of $8.50, suggesting a potential upside of 642.36%. Valneva has a consensus target price of $11.98, suggesting a potential upside of 109.21%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cardiol Therapeutics is more favorable than Valneva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Valneva	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Cardiol Therapeutics has higher earnings, but lower revenue than Valneva. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A
Valneva	$197.56M	2.75	-$130.33M	-$1.87	N/A

Cardiol Therapeutics has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market. Comparatively, Valneva has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market.

In the previous week, Valneva had 5 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 6 mentions for Valneva and 1 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.93 beat Valneva's score of 0.38 indicating that Cardiol Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiol Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Valneva	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Valneva beats Cardiol Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Cardiol Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRDL vs. The Competition

Export

Metric	Cardiol Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$131.96M	$2.96B	$6.42B	$12.34B
Dividend Yield	N/A	1.68%	2.69%	5.22%
P/E Ratio	-4.09	18.01	23.80	24.23
Price / Sales	N/A	311.29	527.67	119.15
Price / Cash	N/A	55.72	41.34	57.13
Price / Book	10.41	3.92	9.99	6.74
Net Income	-$24.20M	$75.85M	$3.56B	$337.06M
7 Day Performance	-10.55%	-2.25%	-1.18%	-0.13%
1 Month Performance	N/A	N/A	N/A	-1.62%
1 Year Performance	-21.03%	22.58%	28.52%	33.25%

Cardiol Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRDL Cardiol Therapeutics	2.3287 of 5 stars	$1.17 +4.0%	$8.50 +629.6%	-14.5%	$134.27M	N/A	N/A	20
GYRE Gyre Therapeutics	1.9967 of 5 stars	$6.06 flat	$17.00 +180.5%	-30.8%	$587.99M	$116.59M	N/A	40	Gap Up
ARVN Arvinas	2.9364 of 5 stars	$9.09 flat	$14.69 +61.6%	+10.0%	$586.50M	$262.60M	N/A	420	Analyst Forecast
CADL Candel Therapeutics	3.2622 of 5 stars	$7.99 flat	$18.00 +125.3%	+53.0%	$585.43M	N/A	N/A	60	Analyst Upgrade
ALT Altimmune	3.0364 of 5 stars	$2.90 flat	$16.67 +474.7%	-47.1%	$563.97M	$40K	N/A	50	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRDL) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cardiol Therapeutics (CRDL) Competitors

CRDL vs. GYRE, ARVN, CADL, ALT, and VALN

How does Cardiol Therapeutics compare to Gyre Therapeutics?

Summary

How does Cardiol Therapeutics compare to Arvinas?

Summary

How does Cardiol Therapeutics compare to Candel Therapeutics?

Summary

How does Cardiol Therapeutics compare to Altimmune?

Summary

How does Cardiol Therapeutics compare to Valneva?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDL vs. The Competition

Cardiol Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cardiol Therapeutics (CRDL) Competitors

CRDL vs. GYRE, ARVN, CADL, ALT, and VALN

How does Cardiol Therapeutics compare to Gyre Therapeutics?

Do insiders & institutionals hold more shares of GYRE or CRDL?

Which has more risk and volatility, GYRE or CRDL?

Do analysts prefer GYRE or CRDL?

Does the media favor GYRE or CRDL?

Is GYRE or CRDL more profitable?

Which has stronger valuation and earnings, GYRE or CRDL?

Summary

How does Cardiol Therapeutics compare to Arvinas?

Which has more risk & volatility, ARVN or CRDL?

Do insiders & institutionals believe in ARVN or CRDL?

Does the media favor ARVN or CRDL?

Do analysts recommend ARVN or CRDL?

Is ARVN or CRDL more profitable?

Which has higher valuation & earnings, ARVN or CRDL?

Summary

How does Cardiol Therapeutics compare to Candel Therapeutics?

Does the media refer more to CRDL or CADL?

Do analysts rate CRDL or CADL?

Is CRDL or CADL more profitable?

Do institutionals & insiders have more ownership in CRDL or CADL?

Which has more risk & volatility, CRDL or CADL?

Which has better earnings and valuation, CRDL or CADL?

Summary

How does Cardiol Therapeutics compare to Altimmune?

Does the media prefer ALT or CRDL?

Is ALT or CRDL more profitable?

Which has more volatility and risk, ALT or CRDL?

Which has preferable valuation & earnings, ALT or CRDL?

Do insiders & institutionals have more ownership in ALT or CRDL?

Do analysts prefer ALT or CRDL?

Summary

How does Cardiol Therapeutics compare to Valneva?

Do insiders & institutionals have more ownership in CRDL or VALN?

Is CRDL or VALN more profitable?

Do analysts prefer CRDL or VALN?

Which has stronger valuation and earnings, CRDL or VALN?

Which has more risk and volatility, CRDL or VALN?

Does the media refer more to CRDL or VALN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDL vs. The Competition

Cardiol Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools